Evidence map›Paper›PMID 37698430›Full record

ArticleMicrobiology spectrum2023

Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis.

Emmanuel Roilides, John S Bradley, Julia Lonchar, Jennifer A Huntington, Prachi Wickremasingha, Feng-Hsiu Su, Christopher J Bruno, Matthew G Johnson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Emmanuel RoilidesThird Department of Pediatrics, Infectious Diseases Unit, School of Medicine, Aristotle University and Hippokration General Hospital , Thessaloniki, Greece.ORCID 0000-0002-0202-364X
John S BradleyDepartment of Pediatrics, University of California, San Diego School of Medicine and Rady Children's Hospital of San Diego , San Diego, California, USA.
Julia LoncharMerck & Co., Inc. , Rahway, New Jersey, USA.
Jennifer A HuntingtonMerck & Co., Inc. , Rahway, New Jersey, USA.
Prachi WickremasinghaMerck & Co., Inc. , Rahway, New Jersey, USA.
Feng-Hsiu SuMerck & Co., Inc. , Rahway, New Jersey, USA.
Christopher J BrunoMerck & Co., Inc. , Rahway, New Jersey, USA.
Matthew G JohnsonMerck & Co., Inc. , Rahway, New Jersey, USA.ORCID 0000-0002-6023-1252
Merck & Co., Inc., Rahway, NJ, USA (United States) · USHippocration General Hospital · GRUniversity of California San Diego · US

Funding

Merck (Merck & Co.)
6 · The paper itself

Abstract

importanceExtrapolation of antibacterial agent pharmacokinetics from adults to newborns and young infants may not be appropriate; similarly, the clinical manifestations of infectious diseases and outcomes following antibacterial treatment may not be similar. Ceftolozane/tazobactam is an antibacterial drug combination active against

Indexed as

ceftolozane/tazobactamcUTIneonatespyelonephritisyoung infants

Identifiers

PMID37698430
PMCPMC10581202
OpenAlexW4386623560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.